Gliclazide

• Description :

  Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Gliclazide is used as an antidiabetic[1].

• Product Name Alternative :

  S1702; SE1702

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  Potassium Channel

• Type :

  Reference compound

• Related Pathways :

  Membrane Transporter/Ion Channel

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/gliclazide.html

• Purity :

  99.58

• Solubility :

  DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL

• Smiles :

  O=S(C1=CC=C(C)C=C1)(NC(NN2CC3C(CCC3)C2)=O)=O

• Molecular Formula :

  C15H21N3O3S

• Molecular Weight :

  323.41

• Precautions :

  H302

• References & Citations :

  [1]Shimoyama, T., et al., Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism, 2006. 55 (6) : p. 722-30.|[2]Lawrence, C.L., et al., Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia, 2001. 44 (8) : p. 1019-25.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [21187-98-4]